Jake Schade, BA | Authors

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

December 22, 2021

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.